Last reviewed · How we verify
NCT05866263: Cognitive
Investigation of the Effect on Cognitive Skills of COVID-19 Survivors
NA trial testing green walking and intelligence gam in COVID-19 in 40 participants. Completed in 17 May 2022.
3 January 2022
Quick facts
| Lead sponsor | Bayburt University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 23 March 2021 |
| Primary completion | 3 January 2022 |
| Estimated completion | 17 May 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- green walking and intelligence gam
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Bayburt University
Who can join
Adults 50 to 70, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigation of the Effect Of Green Walking and Intelligence Games on the Cognitive Skills of Individuals Between the Ages of 50-70 Survived COVID-19 Disease The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05866263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Bayburt University trials
Trials by the same sponsor.
- NCT06838169 — The Effect of Vırtual Realıty Glasses on Heart Faılure Patıents · NA · not yet recruiting
- NCT07268976 — Jackfruit Effects on Adipokines and Cognition in Boxers · NA · completed
- NCT07236346 — Effects of Parent-child Co-participation in Physical Activity · NA · completed
- NCT07254273 — Boccia Exercises and Upper Limb Muscle Adaptations in Hemiparetic Individuals · NA · completed
- NCT06217692 — The Effect of Nutrition Education Hemodialysis Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05866263 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayburt University
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05866263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing